Title |
ERβ1: characterization, prognosis, and evaluation of treatment strategies in ERα-positive and -negative breast cancer
|
---|---|
Published in |
BMC Cancer, October 2014
|
DOI | 10.1186/1471-2407-14-749 |
Pubmed ID | |
Authors |
Jordan M Reese, Vera J Suman, Malayannan Subramaniam, Xianglin Wu, Vivian Negron, Anne Gingery, Kevin S Pitel, Sejal S Shah, Heather E Cunliffe, Ann E McCullough, Barbara A Pockaj, Fergus J Couch, Janet E Olson, Carol Reynolds, Wilma L Lingle, Thomas C Spelsberg, Matthew P Goetz, James N Ingle, John R Hawse |
Abstract |
The role and clinical value of ERbeta1 expression is controversial and recent data demonstrates that many ERbeta antibodies are insensitive and/or non-specific. Therefore, we sought to comprehensively characterize ERbeta1 expression across all sub-types of breast cancer using a validated antibody and determine the roles of this receptor in mediating response to multiple forms of endocrine therapy both in the presence and absence of ERalpha expression. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Science communicators (journalists, bloggers, editors) | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Portugal | 1 | 2% |
Unknown | 57 | 98% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 12 | 21% |
Student > Ph. D. Student | 10 | 17% |
Professor > Associate Professor | 5 | 9% |
Student > Bachelor | 4 | 7% |
Other | 4 | 7% |
Other | 11 | 19% |
Unknown | 12 | 21% |
Readers by discipline | Count | As % |
---|---|---|
Biochemistry, Genetics and Molecular Biology | 16 | 28% |
Medicine and Dentistry | 15 | 26% |
Agricultural and Biological Sciences | 6 | 10% |
Pharmacology, Toxicology and Pharmaceutical Science | 2 | 3% |
Psychology | 2 | 3% |
Other | 3 | 5% |
Unknown | 14 | 24% |